For more information please contact:
Co-Head of Healthcare
Eric B. Cheng
Co-Head of Healthcare
Equity Capital Markets
Head of Equity
Senior Vice President
Senior Vice President
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, has closed a private placement of 683 million ordinary shares (with 1 new option for every 3 new shares issued with an exercise price of $0.054 per new option exercisable on or before 30 November 2022) to professional and sophisticated investors and directors of Imugene Limited. The shares were sold at a price of $0.036 per share representing a 19.8% discount to the weighted average closing price of shares over the 30 trading days prior to 27 November 2019 (being the last trading day before announcement of the Offer).
Imugene Limited intends to use the proceeds for its existing clinical programs including the two oncolytic virus clinical candidates through completion of Phase 2 clinical studies and for working capital purposes. The combination of the capital raising and Imugene Limitedís current financial position supports both the oncolytic virotherapy platform and B-cell immunotherapy through to meaningful proof of concept for corporate partnering discussions.
ROTH Capital Partners acted as U.S. placement agent for the private placement.
About Imugene Limited
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the bodyís immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugeneís immunooncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market. For more information, please visit
www.imugene.com. (Source: Company Press Release |
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and
their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading,
market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and
maintains offices throughout the U.S. For more information on ROTH, please visit
Date of Announcement: 12/24/19
The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC
("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any
companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or
estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be
reproduced in any form without the express written permission of ROTH. Copyright 2019.